药物涂层球囊治疗小冠状动脉病变(BASKET-SMALL 2):一项开放标签随机非劣效性试验
BASKET-SMALL 2为多中心、开放标签、随机非劣效性试验,纳入758例小冠状动脉原发病变(直径<3 mm)且需经皮冠状动脉介入治疗的患者,1:1随机接受药物涂层球囊(DCB)血管成形术或第二代药物洗脱支架(DES)植入,均先行预扩张。主要终点为12个月主要不良心脏事件(MACE,包括心源性死亡、非致死性心肌梗死和靶血管血运重建),非劣效界值为MACE绝对差4%。符合方案人群MACE绝对差的95%CI(-3.83%至3.93%)低于预设界值(p=0.0217),非劣效成立;全分析人群12个月MACE率DCB组7.5% vs DES组7.3%(HR 0.97,95%CI 0.58-1.64,p=0.9180)。
要点
- 小冠状动脉原发病变(直径<3 mm)需PCI者,DCB在12个月MACE上非劣效于第二代DES(符合方案人群绝对差95%CI -3.83%至3.93%,p=0.0217)。
- 全分析人群12个月MACE率DCB组7.5% vs DES组7.3%,HR 0.97(95%CI 0.58-1.64),两组事件率相似。
- 心源性死亡DCB组12例(3.1%)vs DES组5例(1.3%)(全分析人群)。
- 可能的或确定的支架内血栓DCB组3例(0.8%)vs DES组4例(1.1%),HR 0.73(95%CI 0.16-3.26)。
- 大出血DCB组4例(1.1%)vs DES组9例(2.4%),HR 0.45(95%CI 0.14-1.46)。
适用人群与场景
- 纳入:小冠状动脉原发病变(直径<3 mm)且有经皮冠状动脉介入治疗指征的患者,共758例。
诊断标准与关键阈值
- 非劣效界值:MACE绝对差4%。
处置流程与药物剂量
- 所有患者先行预扩张,随后随机1:1接受DCB血管成形术或第二代DES植入。
- 双联抗血小板治疗按现行指南给予。
研究设计与关键结果
- 多中心、开放标签、随机非劣效性试验,758例患者随机分配至DCB组(382例)或DES组(376例),2012年4月10日至2017年2月1日入组。
- 符合方案人群MACE绝对差95%CI为-3.83%至3.93%,低于预设非劣效界值4%(p=0.0217),DCB不劣于DES。
- 全分析人群12个月MACE率:DCB组7.5% vs DES组7.3%,HR 0.97(95%CI 0.58-1.64),p=0.9180。
- 心源性死亡:DCB组12例(3.1%)vs DES组5例(1.3%)。
- 可能的或确定的支架内血栓:DCB组3例(0.8%)vs DES组4例(1.1%),HR 0.73(95%CI 0.16-3.26)。
- 大出血:DCB组4例(1.1%)vs DES组9例(2.4%),HR 0.45(95%CI 0.14-1.46)。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机非劣效性试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于小冠状动脉原发病变(直径<3 mm)且有PCI指征的患者,DCB是DES之外的一种选择,12个月MACE非劣效于DES。
- 原文未报告适用与不适用人群的进一步限定,临床决策需结合具体患者情况。
指南或共识出处
- BASKET-SMALL 2试验,注册号NCT01574534,发表于Lancet。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Drug-coated balloons (DCB) are a novel therapeutic strategy for small native coronary artery disease. However, their safety and efficacy is poorly defined in comparison with drug-eluting stents (DES).
METHODS: BASKET-SMALL 2 was a multicentre, open-label, randomised non-inferiority trial. 758 patients with de-novo lesions (<3 mm in diameter) in coronary vessels and an indication for percutaneous coronary intervention were randomly allocated (1:1) to receive angioplasty with DCB versus implantation of a second-generation DES after successful predilatation via an interactive internet-based response system. Dual antiplatelet therapy was given according to current guidelines. The primary objective was to show non-inferiority of DCB versus DES regarding major adverse cardiac events (MACE; ie, cardiac death, non-fatal myocardial infarction, and target-vessel revascularisation) after 12 months. The non-inferiority margin was an absolute difference of 4% in MACE. This trial is registered with ClinicalTrials.gov, number NCT01574534.
FINDINGS: Between April 10, 2012, and February 1, 2017, 382 patients were randomly assigned to the DCB group and 376 to DES group. Non-inferiority of DCB versus DES was shown because the 95% CI of the absolute difference in MACE in the per-protocol population was below the predefined margin (-3·83 to 3·93%, p=0·0217). After 12 months, the proportions of MACE were similar in both groups of the full-analysis population (MACE was 7·5% for the DCB group vs 7·3% for the DES group; hazard ratio [HR] 0·97 [95% CI 0·58-1·64], p=0·9180). There were five (1·3%) cardiac-related deaths in the DES group and 12 (3·1%) in the DCB group (full analysis population). Probable or definite stent thrombosis (three [0·8%] in the DCB group vs four [1·1%] in the DES group; HR 0·73 [0·16-3·26]) and major bleeding (four [1·1%] in the DCB group vs nine [2·4%] in the DES group; HR 0·45 [0·14-1·46]) were the most common adverse events.
INTERPRETATION: In small native coronary artery disease, DCB was non-inferior to DES regarding MACE up to 12 months, with similar event rates for both treatment groups.
FUNDING: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Basel Cardiovascular Research Foundation, and B Braun Medical AG.
参考来源
- Jeger RV, Farah A, Ohlow MA, et al. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 2018. PMID: 30170854. doi:10.1016/S0140-6736(18)31719-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。